Market research
ALIMP.PA Implanet S.A
PA EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 22M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 0.67
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- FR0013470168
- Market cap
- 22M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 0.67
About
About Implanet S.A
Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally. The company offers spinal and knee products, including Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Olea, Saxxo, Swingo, Shark, Origin, and Jazz Frame, as well as ISS-Jazz Screw systems for posterior fixation. It also provides an ultrasonic osteotomy surgical system; and knee prostheses under the Madison name. The company exports its products. Implanet S.A. was founded in 2006 and is headquartered in Martillac, France.
Research context
Implanet S.A appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ALIMP.PA discussion.
5 years, 6 months ago
Implanet S.A is currently in a long term downtrend where the price is trading 14.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.6.
Implanet S.A's total revenue sank by 0.0% to $2M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-910K since the same quarter in the previous year.
Finally, its free cash flow grew by 2.9% to $-831K since the same quarter in the previous year.
Based on the above factors, Implanet S.A gets an overall score of 2/5.